Recent Updates
Recently added Catalysts
EXEL Neutral Sentiment Score: 60/100

Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026

Wednesday, July 22, 2026 1 min read
Key Takeaway: Exelixis, Inc. will release its second quarter 2026 financial results on August 5, 2026, after market close. A conference call and webcast will follow at 5:00 p.m. ET for management to discuss the results and provide a business update. Access to the event will be available online.

Market Sentiment Analysis

POSITIVE FACTORS

  • Exelixis is actively engaging with investors through a conference call.
  • The scheduled release of financial results indicates transparency.
  • Management will provide a general business update alongside financial results.

Full Press Release Details

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2026 financial results will be released on Wednesday, August 5, 2026 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event will be available via the Internet from the company’s website. To access the conference call, please dial (800) 715-9871 (domes

Frequently Asked Questions

When will Exelixis release its Q2 2026 financial results?

Exelixis will release its Q2 2026 financial results on August 5, 2026.

What time is the Exelixis conference call?

The conference call will take place at 5:00 p.m. ET on August 5, 2026.

How can I access the Exelixis conference call?

Access to the conference call will be available via the company's website.

What will be discussed during the conference call?

Management will discuss the financial results and provide a general business update.

Tags: EXEL Viatris Investor Conferences Healthcare Exelixis financial results conference call August 2026
Last updated: Jul 22, 2026

Biotech snapshot

Cash runway
$777M liquidity · $0M/mo burn
Low dilution risk
Lead asset
XL309Phase 1
Advanced Solid Tumor →